EUVIMEDEUVIMED entdecken
Open Access

Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia

Joshua Tatarian, Natalie Tupper, Peng Li, Julie Feusier, Maryam Abdo, Stephen Hyter, Patrick R Gonzales, Da Zhang, Janet Woodroof, Sarah Kelting, Andrew K Godwin iD, Wei Cui iD

American Journal of Clinical Pathology · 02.11.2023 · 160 (5) · 490-499

DOI: 10.1093/ajcp/aqad077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.07.2023. Verfasst von Joshua Tatarian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, US. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

SRSF2 mutations are known to be associated with poor outcomes in myelodysplastic neoplasm, but studies on their prognostic impact on acute myeloid leukemia (AML) remain limited. In this retrospective study, we analyzed clinical and pathologic characteristics of patients with AML and correlated the outcomes with SRSF2 mutations.

Methods

We characterized the morphologic, immunophenotypic, molecular, and clinical findings in AML with mutated SRSF2 and compared them with SRSF2 wild-type (WT) myeloid neoplasms (MNs).

Results

Using next-generation sequencing, we identified 134 patients with MNs and SRSF2 mutations (85 with AML and 49 with MNs) in addition to 342 SRSF2-WT AMLs. Fifty-two (62%) patients with altered SRSF2 demonstrated a variable degree of morphologic dysplasia. The most frequent immunophenotypic aberrancies in SRSF2-mutant AML included diminished CD33 expression and overexpression of CD7, CD56, or CD123, similar to WT AML. More IDH1/2 (P = .015) and NPM1 (P = .002) mutations were seen in SRSF2-mutant AML than in SRSF2-mutant non-AML. Further, more IDH1/2, ASXL1, RUNX1, and STAG2 mutations were observed in SRSF2-mutant AML than in SRSF2-WT AML (P < .0001 to P = .001). Finally, patients with SRSF2-mutant AML showed a significantly worse overall survival (OS) than patients with SRSF2-WT AML (P < .0001), but this worse OS appeared to be rescued by allogeneic stem cell transplant (allo-SCT).

Conclusions

Acute myeloid leukemia with altered SRSF2 shows a variable degree of morphologic dysplasia without uniform immunophenotypic aberrancies. SRSF2 mutations appear to be independent poor prognostic factors, but allo-SCT has improved the clinical outcomes in patients with SRSF2-mutant AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansRetrospective StudiesPrognosisRNA-Binding ProteinsMutationMolecular BiologySerine-Arginine Splicing Factors

Stichwörter der Autor:innen

SRSF2AMLNGSflow cytometrysomatic mutation

Substanzen

RNA-Binding ProteinsSRSF2 protein, humanSerine-Arginine Splicing Factors

Autor:innen und Institutionen

  • Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, US.
  • Division of Hematopathology, Department of Pathology, University of Utah, Salt Lake City, UT, US.
  • Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, US.

ORCID-Profile: Andrew K Godwin, Wei Cui

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • Kansas Institute for Precision Medicine Center
  • National Institutes of Health
  • National Cancer Institute
  • Kansas Bioscience Authority

Zitieren

APA

Tatarian, J., Tupper, N., Li, P., Feusier, J., Abdo, M., Hyter, S., Gonzales, P. R., Zhang, D., Woodroof, J., Kelting, S., Godwin, A. K., & Cui, W. (2023). Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia. American Journal of Clinical Pathology, 160(5), 490-499. https://doi.org/10.1093/ajcp/aqad077

Vancouver

Tatarian J, Tupper N, Li P, Feusier J, Abdo M, Hyter S, et al. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia. American Journal of Clinical Pathology. 2023;160(5):490-499. doi:10.1093/ajcp/aqad077

BibTeX
@article{Tatarian2023,
  author = {Tatarian, Joshua and Tupper, Natalie and Li, Peng and Feusier, Julie and Abdo, Maryam and Hyter, Stephen and Gonzales, Patrick R and Zhang, Da and Woodroof, Janet and Kelting, Sarah and Godwin, Andrew K and Cui, Wei},
  title = {Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  volume = {160},
  number = {5},
  pages = {490--499},
  doi = {10.1093/ajcp/aqad077}
}
Kostenlos starten →